Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from OncoSil Medical Ltd ( (AU:OSL) ) is now available.
OncoSil Medical Ltd announced an update regarding the issuance of securities under a Securities Purchase Plan (SPP), which was approved by shareholders during an Extraordinary General Meeting (EGM) held on July 8, 2025. This update includes an amendment to the number of shares and options, reflecting a 1 for 400 consolidation approved earlier on May 29, 2025, and the final SPP issue price announced on July 7, 2025. This move is part of the company’s strategic financial adjustments, potentially impacting its market positioning and shareholder value.
More about OncoSil Medical Ltd
OncoSil Medical Ltd operates in the medical industry, focusing on developing and commercializing innovative medical devices. The company’s primary product is a targeted radioactive isotope treatment for pancreatic and liver cancer, aiming to improve patient outcomes through advanced therapeutic solutions.
Average Trading Volume: 42,531
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$16.71M
Learn more about OSL stock on TipRanks’ Stock Analysis page.